The exploration of novel antitumor agents that could not only inhibit the activation of NF-κB but also sensitize cells to GEM and target the malignant behavior of pancreatic cancer to improve the current treatment effect is urgently needed. Here, NFKB1 is linked to pancreatic neoplasm.